Pregnancy in Osteogenesis Imperfecta (OI) Registry

Status Completed

Clinical Trial Summary

The purpose of this study is to learn about pregnancy outcomes in osteogenesis imperfecta (OI). Patients enrolled in the Brittle Bone Disorders (BBD) Contact Registry (CR) will be invited via email to participate in this study.

Clinical Trial Description

Population: The RDCRN BBD Contact Registry helps researchers identify and recruit patients who are eligible for participation in future research studies. People eligible for enrollment in the RDCRN BBD Contact Registry include patients and parents of patients with Brittle Bone Disorders. All patients with BBD from the United States and around the world are encouraged to join.

Survey Administration: The investigators will administer a review of pregnancy outcomes survey and delineate the outcomes in pregnancies complicated by varying forms of OI. Patients will be sent an email invitation describing the study. If the participant wants to participate and is eligible, she will follow the survey link in the email message, which directs her to an IRB-approved online consent form. A unique survey link will be generated for each participant and included in the survey invitation, which is a customized email message. This link will allow the investigators to determine who completed the survey. The investigators will send repeat email invitations every two months (total of 3 invitations) to those invitees who have not yet participated. The investigators will allow approximately 6 months for enrollment and survey completion and expect that the study will close soon thereafter.

Data: The survey data will be collected and stored at the Rare Diseases Clinical Research Network's Data Management and Coordinating Center (DMCC) at the University of South Florida. All data collected will be sent to the database of Genotypes and Phenotypes (dbGaP) to be stored indefinitely. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03072303
Study type	Observational
Source	University of South Florida
Contact
Status	Completed
Phase
Start date	June 16, 2017
Completion date	September 13, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03557567` - NGS Strategy Effectiveness in Molecular Diagnosis
Not yet recruiting	`NCT05559801` - Mesenchymal Cell Therapy in Osteogenesis Imperfecta (OI)	Phase 1/Phase 2
Active, not recruiting	`NCT02531087` - Urinary Biomarkers of OI Pathobiology
Completed	`NCT01713231` - Effect of High-Dose Vitamin D on Bone Density in Osteogenesis Imperfecta	Phase 4
Completed	`NCT00655681` - Prevention of Post Operative Bone Loss in Children	N/A
Recruiting	`NCT06065111` - Study of Osteogenesis Imperfecta Tendon
Withdrawn	`NCT03216486` - An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta	Phase 2
Recruiting	`NCT06086613` - A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers	Phase 1
Completed	`NCT04009733` - Epigenetic Regulation of Osteogenesis Imperfecta Severity : miROI Study	N/A
Completed	`NCT04231916` - High Resolution Thermal Imaging to Identify Vertebral Fractures in Children and Young People With Osteogenesis Imperfecta	N/A
Active, not recruiting	`NCT02814591` - Development of a Non-invasive Assessment of Human Bone Quality Using Spatially Offset Raman Spectroscopy
Completed	`NCT00982124` - An Efficacy and Safety Trial of Intravenous Zoledronic Acid in Infants Less Than One Year of Age, With Severe Osteogenesis Imperfecta	Phase 3
Completed	`NCT00001305` - Growth Hormone Therapy in Osteogenesis Imperfecta	Phase 3
Completed	`NCT04119388` - Evaluation of the Benefits of Adaptive Physical Activity in Children and Adolescents With Osteogenesis Imperfecta	N/A
Terminated	`NCT01679080` - The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta	Phase 2
Completed	`NCT00106028` - Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children	Phase 3
Recruiting	`NCT04152551` - Effects of Bisphosphonates on OI-Related Hearing Loss	Phase 4
Completed	`NCT00705120` - Treatment of Severe Osteogenesis Imperfecta by Allogeneic Bone Marrow Transplantation	Phase 1
Recruiting	`NCT04169568` - Osteogenesis Imperfecta Blood Pressure Study
Completed	`NCT03064074` - Safety of Fresolimumab in the Treatment of Osteogenesis Imperfecta	Phase 1